Project JAY THA Registration Study

Rheumatoid Arthritis Clinical Trial

Official title:

A Prospective, Randomized, Multicenter Clinical Study in Chinese Subjects to Compare the Safety and Efficacy of the Delta PLUS Femoral Head and SL-TWIN Stem With BIOLOX Forte Ball Head and SL-PLUS Stem in Total Hip Arthroplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02347384
• Other study ID #: 14-4560-02
• Status: Completed
• Phase: N/A
• First received: January 9, 2015
• Last updated: November 13, 2017
• Start date: April 20, 2015
• Est. completion date: November 1, 2016

Study information

• Verified date: November 2017
• Source: Smith & Nephew Orthopaedics (Beijing) Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, multicenter clinical study in Chinese subjects to compare the safety and efficacy of the Delta PLUS Femoral Head and SL-TWIN Stem with BIOLOX forte ball head and SL-PLUS Stem in total hip arthroplasty

Description:

As the incidence of joint disease continues to increase, an ever growing percentage of the affected population will undergo total hip arthroplasty (THA). This recent upward trend for THA procedures appears to be directly related to the prevalence of certain health factors. Specifically, longer life spans, rising obesity rates, and increasing physical activity levels in relatively younger populations are all examples of factors that may significantly contribute to hip degeneration. While strategies such as weight reduction, lifestyle change, or drug therapy may offer temporary relief from the symptoms of joint degeneration, THA remains the standard of care for subjects experiencing significant losses in quality of life due to advanced hip disease.

There has been an increase in imported hip prostheses during the past decade, so that surgeons now have more choices of implants. However, the high cost of imported prostheses has become a barrier to the development of hip replacement in China and caused many patients requiring immediate hip replacement to have to delay or miss their surgery. The development and promotion of high-quality domestic joint implants and surgical instruments is the key to the development of joint replacement technique in China.

The primary objective of this study is to demonstrate non-inferiority of subjects implanted with the Delta PLUS Femoral Head + SL-TWIN Stem compared to a randomized concurrent control group of subjects implanted with the BIOLOX forte ball head + SL-PLUS Stem in terms of mean Harris Hip Score (HHS) at 1 year.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: November 1, 2016
• Est. primary completion date: November 1, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male or female subjects, aged between 50 and 75 years inclusive of Chinese ethnicity.

• Subject presents with osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, avascular necrosis of hip joint, developmental dysplasia of the hip, or femoral neck fracture requiring primary total hip replacement.

• Subject who is able to give voluntary, written informed consent to participate in the study and from whom consent has been obtained by signing and dating an EC-approved consent form.

• Subject who is able to understand this clinical study, co-operates with the investigational procedures and is willing to return to the hospital for all the required post-operative follow-ups for up to 12 months.

• Life expectancy of subject is over 2 years.

Exclusion Criteria:

• Bilateral hip disease with the anticipated need for bilateral hip implant during study participation (i.e., within the next 12 months).

• Subject experienced prior joint replacement surgery on any major joint (hip, knee) in lower limb within the last 12 months.

• Subject with developmental dysplasia of the hip of CROWE grade 3 or 4.

• Subject has known or suspected metal sensitivity.

• Subject is known to have insufficient bone stock resulting from conditions such as cancer, significant osteoporosis or metabolic bone disorders, which cannot provide adequate support and/or fixation to the prosthesis.

• Subject is severely obese (BMI>35).

• Subject had an active infection or sepsis (treated or untreated).

• Subject has conditions that may compromise implant stability or postoperative recovery (i.e., Paget's or Charcot's disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency, hip abduction muscle strength less than grade IV or complete loss, or neuromuscular disease).

• Subject has an emotional or neurological condition that would affect their ability or willingness to participate in the study (e.g. cognitive disorder, mental illness, mental retardation).

• Subject is immunosuppressed, has an autoimmune disorder, or an immunosuppressive disorder. For examples, subject is on immunosuppressive therapy (corticosteroid hormones in large amounts, cytotoxic drugs, antilymphocytic serum or irradiation in large doses) or has acquired immunodeficiency syndrome (AIDS).

• Subject is known to be at risk for lost to follow-up, or failure to return for scheduled visits.

• Subject was enrolled in another investigational drug, biologic, or device study in the last 12 months.

• Subject is a woman who is pregnant or lactating,or intends to become pregnant during the course of the study.

• Known alcohol and/or drug abuse

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Avascular Necrosis
• Developmental Dysplasia of the Hip
• Femoral Neck Fracture
• Femoral Neck Fractures
• Hip Dislocation, Congenital
• Necrosis
• Osteoarthritis
• Post-traumatic Arthritis
• Rheumatoid Arthritis

Intervention

Device:
• Delta PLUS Femoral Head + SL-TWIN Stem
Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head & SL-TWIN Stem
• BIOLOX forte ball head + SL-PLUS Stem
Subject will undergo total hip arthroplasty with BIOLOX forte ball head & SL-PLUS Stem

Locations

Country	Name	City	State
China	Inner Mongolia Bao Gang Hospital	Baotou	Inner Mongolia
China	Luoyang Orthopedic-Traumatological Hospital	Luoyang	Henan
China	The First Teaching Hospital of Xinjiang Medical University	Ürümqi	Xinjiang
China	Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region	Ürümqi	Xinjiang

Sponsors (1)

Lead Sponsor	Collaborator
Smith & Nephew Orthopaedics (Beijing) Limited

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The Western Ontario and McMaster Universities Arthritis Index(WOMAC)		1 year post-operative
Other	SF-12 Health Survey		1 year post-operative
Other	Number of adverse events		Up to 1 year post-operative
Primary	Harris Hip Score		1 year post-operative
Secondary	Composite Clinical Success, as indicated by A) No revision of any device component; and B) Total Harris Hip Score greater than or equal to 80 (excellent to good score); and C) Radiologic success.	A successful individual outcome for a subject in total hip arthroplasty will be characterized at 1 year postoperative by a composite of three success criteria: A. No revision of any device component; and B. Total Harris Hip Score greater than or equal to 80 (excellent to good score); and C. Radiologic success.	1 year post-operative